About Us

Blue Blood Biotech Corporation derives its name from the precious and noble nature of

blood.Based on sound knowledge and can-do attitude,we are diligently developing our

core competenceon plasma-derived and recombinant protein platforms and diagnostic

reagent.  And through these platform technologies, we shall able to continue delivering

life-saving medicine to benefit patents and improve the quality of life.

                                                                                                                              TOP 

History

2000 Blue Blood Biotechnology Corp. was founded
2001 Collaborated with National Cheng Kung University and National Taiwan University
  in developing anti-Enterrovirus type-71 (EV-71) and anti-Cytomegalorvirus (CMV)
  intravenous immunoglobulin (IVIG) products
2003 Established an R& D lab at incubator in National Cheng Kung University and
  completed bench-scale development work for intravenous immunoglobulin.
  Awarded SBIR grant by Department of Industrial Technology of MOEA in
  developing IVIG process.
2004 Relocated the R&D lab to, and established a pilot facility at the SME incubator
  at Tainan Science Park . -Completed pilot-scale IVIG process development.
2005 Change name to Blue Blood Biotech Corp. -Licensed novel epidermal
  growth factor (NEGF) from Professor Hua-Lin Wu at National Cheng Kung
  University.For his contribution, Professor Wu, was awarded the Excellent
  Contributions inTechnology Transfer Award sponsored by National Science
  Council.
2006 Started development work for recombinant NEGF for wound healing
2007 1. Awarded grant funding of $50m NTD for NEGF product development project
  from Bureau of Industrial Technology of MOEA.
2. Formed strategic alliance with ProMetic Life Science Inc. to implement the
  proprietaryhigh yield fractionation technology to develop plasma-derived
  therapeutics for Taiwan and Southeast Asian Markets.
3. Completed manufacturing cell banks of NEGF product in compliance with
  current Good Manufacturing Practice (cGMP) at Charles River Laboratories, Inc.
2008 1. Completed training and scaling up at 150L for recombinant NEGF at Wanxing
  Bio-Pharmaceuticals's GMP facility.
  2. Completed production of the anti- EV-71 hyper immune IVIG.
  3. Signed Letter Of Intent with ProMetic Life Science Inc. to develop anti-
    Cytomegalovirus (CMV) immunoglobulin product
  4. Patent application of “A composition for wound healing and use thereof”was
    granted by South Africa Patent Office.
  5. MOEA approved NEGF product development project is qualified for
    governmental incentives under “Biotech and New Pharmaceutical Development
    Act”.
2009 1. Collaborated with Yung Shin Pharm. IND. CO., LTD. in scaling up at 30L for
  recombinant NEGF fermentation.
2 .Collaborated with Department of Biotechnology of Southern Taiwan University
  in scaling up at 100L for recombinant NEGF fermentation.
3. Collaborated with Walter Reed Army Institute of Research, USA in scaling up
  at 100L for recombinant NEGF fermentation and purification process at GMP
  facility.
4. Patent application of “Methods and compositions for bactericide, bacteriostatic
  and anti-inflammation” was granted by South Africa Patent Office.
5. Patent application of “A composition for wound healing and use thereof” was
  granted by State Intellectual Property Office of the People’s Republic of China.
6. NEGF product development project was selected as Key Project by
  Biotechnology and Pharmaceutical Industries Promotion Office, MOEA to
  provide customization service and assist strengthening promotion work.
2010 1. Center of Drug Evaluation, Taiwan provided “Index Cases Consultation
    Services” for NEGF product development project from 2010 until now.
  2. Collaborated with Department of Biomedical Imaging and Radiological
    Sciences of National Yang-Ming University in Pharmacokinetics study for
    recombinant NEGF.
  3. Collaborated with MycoMagic Biotechnology in fermentation of preclinical
    test article for recombinant NEGF.
  4. Collaborated with Animal Technology Institute Taiwan in wound healing
    mechanism study for recombinant NEGF.
  5. Patent application of “A composition for wound healing and use thereof”
    was granted by Intellectual Property Office of Singapore and IP Australia.
  6. Patent application of “Methods and compositions for Promoting
    Angiogenesis” was granted by United States Patent and Trademark Office.
  7. MOEA approved Acnex project is qualified for governmental incentives
    under “Biotech and New Pharmaceutical Development Act”.
  8. Signed contract with Cytovance Biologics, Inc. for phase I drug substance
    cGMP production of recombinant NEGF, and started to process and analytical
    method technology transfer.
  9. Signed contract with Dow Pharmaceutical Sciences, Inc. for phase I drug
    product cGMP production of recombinant NEGF, and started to process and
    analytical method technology transfer.
2011 1. Patent application of “A composition for wound healing and use thereof” was
  granted by Korean Intellectual Property Office. (Apr)
2. Patent application of “Dextromethorphan-Based Method for Treating Acne” was
  granted by United States Patent and Trademark Office.(May)
3. Patent application of “A composition for wound healing and use thereof” was
  granted by Japan Patent Office.(Aug)
4. Patent application of “Methods and compositions for bactericide,bacteriostatic
  and anti-inflammation” was granted by Intellectual Property Office of Singapore.
  (Nov)
  Attend pre-IND meeting with US FDA for topical recombinant NEGF (BB-101)
  for the treatment of diabetic foot ulcer.(Nov)
5. Patent application of “Methods and compositions for bactericide, bacteriostatic
  and anti-inflammation” was granted by IP Australia.(Dec)
2012 1. Patent application of “Methods and compositions for bactericide,
  bacteriostatic and anti-inflammation” was granted by European Patent Office.
  (Jan)
2. Patent application of “Methods and compositions for bactericide, bacteriostatic
  and anti-inflammation” was granted by Taiwan Intellectual Property Office.(Mar)
3. Conducted a GLP-compliance study: “A 28-day Study of NEGF by Subcutaneous
  Injection in Rats with a 16-day Recovery Period” at Charles River Laboratories
  , Inc.(Apr)
4. Engaged Associate Professor Chuan-Liang Kao as technical consultant in
  developing Neutralization assay and antibody screening diagnostic kit for
  Cytomegalovirus.(Jun)
5. Awarded grant funding of $15m NTD for “Preclinical Study Program for
  Wound Therapy Protein Drug BB-101” from Department of Industrial
  Technology of MOEA.(Sep)
6. Patent application of “Method for treating wounds using an EGF-like domain
  of Thrombomodulin” was granted by United States Patent and Trademark
  Office.(Oct)
  Patent application of “Methods and compositions for treating ischemia” was
  granted by United States Patent and Trademark Office.(Oct)
  Patent application of “Methods and compositions for bactericide, bacteriostatic
  and anti-inflammation” was granted by State Intellectual Property Office of
  the People’s Republic of China.(Oct)
2013 1. The ongoing NEGF protein preclinical study was successfully awarded the
    Industrial R&D Promotional Loans of 27 Million NT Dollars from Industrial
    Development Bureau, Ministry of Economic Affairs.(April)
  2. In collaboration with Charles River Laboratories, U.S.A, BlueBlood effectively
    conducted the 28-day repeat dose dermal toxicity study in mini-pigs.(April)
  3. BlueBlood has partnered with Dow Pharmaceuticals Sciences (U.S.A) on GMP
    manufacturing of Phase I clinical supplies.(April)
  4. Patent application of “A composition for wound healing and use thereof” was
    granted by Taiwan Intellectual Property Office(May)
  5. Patent application of “Methods and compositions for bactericide,bacteriostatic
    and anti-inflammation” was granted by Korean Intellectual Property Office. (June)
  6.Patent application of “Methods and compositions for bactericide, bacteriostatic
    and anti-inflammation” was granted by Japan Patent Office. (June)
   

 

 

                                                                                                                              TOP 

Management

 

Eugene Huang, Chairman

Huang is the Chairman of Jim Brother’s Corporation. And the chairman

of Hung Yuen Enterprise Co., Ltd.

  

Chuan-Chi Chiang, Ph.D., MBA, President

Also severs as Executive Director of Neonatal Screening Center and

Divisional Director of Research & Clinical Laboratory at Chinese Foundation

of Health since ‘93.

Prior to the current position, he was Chief of Division of Biologics, Bureau

of Food and Drug Analysis, DOH.

          

Min-Long Lai, Ph.D., Assistant Manager of R&D department

Also serves as President, Union Clinbio Lab Int’l Co., Ltd.

Instructor, National Yang-Ming University.

                                                                                                                              TOP 

Consultants

 

Hua-Lin Wu, Ph.D.

Dr. Wu is a professor of Biochemistry Department of National Cheng-Kung

University. Professor Wu is specialized in enzymology, protein chemistry,

protease in clinical biochemistry, cardiovascular disease and etc..

 

Tom Chen Ph.D.

Dr. Chen is the vice president of process development division of Prometic

BioTherapeutics company. Dr. Chen was the chief director of process

development of plasma-derived products division of American Red Cross

Association and the chief leader of medical science division of EntreMed

company. Dr. Chen is experienced in developments of plasma-derived

product. He held lots of research and development program of plasma-

derived products. Besides, he also led the development of multiple protein

drugs. He is experienced in fermentation production and purification of

proteins. Dr. Cheng is experienced in development affairs and familiar with

multiple international corporations.

 

Associate Professor Chuan-Liang Kao

Kao is an associate professor of School of Medical Technology, College

of Medicine, National Taiwan University and director of Clinical Virology,

Department of Laboratory Medicine, National Taiwan University Hospital.

Professor Kao is specialized in clinical virology, laboratory diagnosis, viral

diagnostic methods invention

 

Shi, Guey-Yueh Ph.D.

Dr. Shi is a professor of Biochemistry Department of National Cheng-Kung

University. Professor Shi is specialized in clinical biochemistry, transgene

technology, gene regulatory, signal transduction, clotting and thrombolytic-

associated protein research.

 

                                                                                                                              TOP